ArticlePloS one2018
Iron chelating properties of Eltrombopag: Investigating its role in thalassemia-induced osteoporosis.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 31 citations in OpenAlex.
- Bone Health Impairment in Patients with Hemoglobinopathies: From Biological Bases to New Possible Therapeutic Strategies.International journal of molecular sciences · 2024Review
- CB2 Receptor as Emerging Anti-Inflammatory Target in Duchenne Muscular Dystrophy.International journal of molecular sciences · 2023Article
- Long term use of eltrombopag in children with chronic immune thrombocytopenia: extended real life retrospective multicenter experience of the Italian Association of Pediatric Hematology and Oncology.Frontiers in medicine · 2023Article
- The efficacy and the safety of eltrombopag in pediatric patients with severe aplastic anemia: a systematic review.Frontiers in pediatrics · 2023Review
- Emerging Roles of the Iron Chelators in Inflammation.International journal of molecular sciences · 2022Review
- Long-term eltrombopag for bone marrow failure depletes iron.American journal of hematology · 2022Article
- Eltrombopag in paediatric immune thrombocytopenia: Iron metabolism modulation in mesenchymal stromal cells.British journal of haematology · 2022Article
- Efficacy and Immunomodulating Properties of Eltrombopag in Aplastic Anemia following Autologous Stem Cell Transplant: Case Report and Review of the Literature.Pharmaceuticals (Basel, Switzerland) · 2022Article
- Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) for the Management of Endocrine Complications in Patients with Haemoglobinopathies.Journal of clinical medicine · 2022Article
- Eltrombopag inhibits TET dioxygenase to contribute to hematopoietic stem cell expansion in aplastic anemia.The Journal of clinical investigation · 2022Article
- Iron status influences the response of cord blood megakaryocyte progenitors to eltrombopag in vitro.Blood advances · 2022Article
- Alteration of osteoclast activity in childhood cancer survivors: Role of iron and of CB2/TRPV1 receptors.PloS one · 2022Article
- Exploring the Potential of Eltrombopag: Room for More?Frontiers in pharmacology · 2022Article
- Research status of biodegradable metals designed for oral and maxillofacial applications: A review.Bioactive materials · 2021Review
- Osteosarcoma in Children: Not Only Chemotherapy.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Hepcidin induces intestinal calcium uptake while suppressing iron uptake in Caco-2 cells.PloS one · 2021Article
- Effects of Eltrombopag on In Vitro Macrophage Polarization in Pediatric Immune Thrombocytopenia.International journal of molecular sciences · 2020Article
- Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in TurkeyTurkish journal of haematology : official journal of Turkish Society of Haematology · 2020Article
- Effective treatment of refractory acquired pure red blood cell aplasia with eltrombopag and sirolimus: a case report.Therapeutic advances in hematology · 2020Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic blood transfusions are responsible to cause iron overload, which leads to several complications to end organs and osteoporosis. Iron chelation is needed to remove iron excess and to contain bone-mass loss. Deferasirox is the most recent oral iron chelator that prevents transfusion related iron overload complications. Recently Eltrombopag (ELT) iron chelating properties are emerging. ELT is an agonist at Thrombopoietin receptor, used in treatment of thrombocytopenia. We tested ELT and Deferasirox in iron overloaded osteoclasts from thalassemic patients and donors measuring intracellular iron, TRAP expression and osteoclast activity. We confirmed ELT iron chelation capacity also in bone tissue and a synergic effect when used with Deferasirox. Moreover, having demonstrated its effects on osteoclast activity, we suggest for the first time that ELT could ameliorate bone tissue's health reducing bone mass loss.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.